Mechelen, Belgium; 4 December 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced a share capital increase arising from warrant exercises.
Galapagos issued 63,500 new ordinary shares on 4 December 2015, for a total capital increase (including issuance premium) of €590,800.00.
Pursuant to the rules of the warrant exercise program of Galapagos’ Executive Committee adopted in 2013, Executive Committee members automatically are committed to exercise a minimum number of warrants, subject to certain conditions. Accordingly, CEO Onno van de Stolpe exercised 10,000 warrants and has consequently increased his holding to a total of 538,289 shares; two other Executive Committee members exercised an aggregate amount of 5,000 warrants.
In accordance with Belgian transparency legislation[1], Galapagos notes that its total share capital currently amounts to € 211,388,857.22; the total number of securities conferring voting rights is 39,076,342, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 2,805,692, which equals the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises three Phase 2, three Phase 1 and five pre-clinical, and 20 discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We are focused on the development and commercialization of novel medicines that will improve people’s lives. The Galapagos group, including fee-for-service subsidiary Fidelta has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
